## Merck Acquires Terns Pharma for $6.7B to Bolster Pipeline as Keytruda Patent Cliff Looms
Merck is making a major strategic move to fortify its oncology portfolio, announcing its intent to acquire Terns Pharmaceuticals for $6.7 billion. The deal, priced at $53 per share, represents a 6% premium over Terns' recent closing price and centers on the promising leukemia drug TERN-701. Terns' stock had already surged six-fold in the preceding six months, driven by the blockbuster potential of this single asset. For Merck, the acquisition is a direct response to the impending loss of patent protection and revenue from its foundational cancer immunotherapy, Keytruda, signaling a critical effort to deepen its cancer drug pipeline ahead of a significant financial transition.

The transaction underscores the high-stakes race among pharmaceutical giants to secure next-generation therapies. Merck's $6.7 billion bet on a single clinical-stage asset highlights the intense pressure to replenish pipelines as multi-billion-dollar drugs face exclusivity cliffs. The premium paid, while modest relative to the recent stock run-up, secures a key contender in the competitive leukemia treatment landscape.

This deal reflects a broader pattern of strategic consolidation within the industry, where large-cap pharma companies are aggressively acquiring innovative biotechs to offset looming revenue losses. The focus on TERN-701 illustrates the premium placed on clinical assets with transformative potential in high-need oncology areas. The move places immediate scrutiny on the integration of Terns' research and the subsequent development timeline for TERN-701, as Merck's future oncology revenue growth becomes increasingly dependent on the success of such acquired pipelines.
---
- **Source**: STAT News
- **Sector**: The Vault
- **Tags**: merck, terns_pharmaceuticals, m&a, oncology, keytruda
- **Credibility**: unverified
- **Published**: 2026-03-25 13:57:30
- **ID**: 33440
- **URL**: https://whisperx.ai/en/intel/33440